

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
---------------------------	-------	--

I hereby appoint the following:

Narinder S. Banait	Reg. No. 43,482
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Leanne C. Price	Reg. No. 42,090
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

**LEGAL DEPARTMENT
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE, PALO ALTO, CA 94304**

TEL: 650-855-0555 FAX: 650-849-8886

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**Sole Inventor or
First Joint Inventor:**

Full name: **PREETI LAL**
Signature: Preeti Lal
Date: 4/27/, 1999
Citizenship: India
Residence: Santa Clara, California
P.O. Address: 2382 Lass Drive
Santa Clara, California, 95054

Second Joint Inventor:

Full name: **PURVI SHAH**
Signature: Purvi Shah
Date: 4/20, 1999
Citizenship: India
Residence: Sunnyvale, California
P.O. Address: 1608 Queen Charlotte Drive, #5
Sunnyvale, California, 94087

Third Joint Inventor:

Full name: **NEIL C. CORLEY**
Signature: Neil C. Corley
Date: APRIL 20, 1999
Citizenship: United States of America
Residence: Mountain View, California
P.O. Address: 1240 Dale Avenue, #30
Mountain View, California, 94040

"Express Mail" mailing label number **EL 856 156 385 US** I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on August 9, 2001.

By: Nancy Ramos Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: HUMAN PREPRONEUROTENSIN/NEUROMEDIN N

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Commissioner for Patents
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),
REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 010020, Frame 0145, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Matthew R. Kaser	Reg. No. 44,817

Lynn E. Murry
Shirley A. Recipon
Susan K. Sather
Michelle M. Stempien
David G. Streeter
Stephen Todd
P. Ben Wang

Reg. No. 42,918
Reg. No. 47,016
Reg. No. 44,316
Reg. No. 41,327
Reg. No. 43,168
Reg. No. 47,139
Reg. No. 41,420

Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304


and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Genomics, Inc.,
Phone: (650) 845-4639, Fax: (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: August 8, 2001

By: 
Lee Bendekgey
VP, General Counsel/Corporate Secretary

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on June 21, 2001.

By: [Signature]
Printed: Katherine Stofer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: HUMAN PREPRONEUROTENSIN/NEUROMEDIN N

Serial No.: 09/002,114 Filing Date: December 31, 1997

Examiner: Clemens, K. Group Art Unit: 1644

Commissioner for Patents
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),
REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 010020, Frame 0145, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings
Michael C. Cerrone
Diana Hamlet-Cox
Richard C. Ekstrom
Barrie D. Greene
Matthew R. Kaser

Reg. No. 36,749
Reg. No. 39,132
Reg. No. 33,302
Reg. No. 37,027
Reg. No. 46,740
Reg. No. 44,817

Lynn E. Murry
Shirley A. Recipon
Susan K. Sather
Michelle M Stempien
David G. Streeter
Stephen Todd
Christopher Turner
Peng Ben Wang

Reg. No. 42,918
Reg. No. 47,016
Reg. No. 44,316
Reg. No. 41,327
Reg. No. 43,168
Reg. No. 47,139
Reg. No. 45,167
Reg. No. 41,420

Please direct all correspondence to:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: David G. Streeter, Ph.D., Incyte Genomics, Inc., Phone: (650) 855-0555, Fax: (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: June 21, 2001

By: Lee Bendekgey
Lee Bendekgey
VP, General Counsel/Corporate Secretary